-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L4swAx43+aTM+81heRsskMGncAJfXKoftCsJ3h3bKYwWiYf7DgE+HyL55Vd6Us12 CCyJgdRlv/gwUibvwx4Xww== 0000950134-03-013919.txt : 20031024 0000950134-03-013919.hdr.sgml : 20031024 20031024133012 ACCESSION NUMBER: 0000950134-03-013919 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20031024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KV PHARMACEUTICAL CO /DE/ CENTRAL INDEX KEY: 0000057055 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 430618919 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-106294 FILM NUMBER: 03956026 BUSINESS ADDRESS: STREET 1: 2503 S HANLEY RD CITY: ST LOUIS STATE: MO ZIP: 63144 BUSINESS PHONE: 3146456600 MAIL ADDRESS: STREET 1: 2503 S HANLEY RD CITY: ST LOUIS STATE: MO ZIP: 63144 424B3 1 c80281b3e424b3.txt PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(B)(3) Registration No. 333-106294 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED OCTOBER 14, 2003 $200,000,000 2.5% CONTINGENT CONVERTIBLE SUBORDINATED NOTES DUE 2033 AND CLASS A COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTES [KV LOGO] K-V PHARMACEUTICAL COMPANY --------------- This document supplements our prospectus dated October 14, 2003 (the "prospectus"), relating to $200,000,000 aggregate principal amount of our 2.5% Contingent Convertible Senior Notes Due 2032 (the "Notes") and the Class A common stock issuable upon conversion of the Notes. You should read this prospectus supplement in conjunction with the accompanying prospectus, which is to be delivered by selling securityholders to prospective purchasers along with this prospectus supplement and any other prospectus supplements. The information in the following table supplements the information under the caption "Selling Securityholders" in the prospectus by (i) substituting the information contained in this Supplement No. 1 for the information contained in the prospectus with respect to Polaris Vega Fund L.P. and Sunrise Partners Limited Partnership, and (ii) supplementing the information contained in the prospectus with the information contained in this Supplement No. 1 with respect to the securityholders other than Polaris Vega Fund L.P. and Sunrise Partners Limited Partnership listed below.
AGGREGATE CLASS A CLASS A PRINCIPAL COMMON STOCK COMMON AMOUNT PERCENTAGE BENEFICIALLY STOCK OF NOTES THAT OF NOTES OWNED BEFORE REGISTERED NAME MAY BE SOLD OUTSTANDING CONVERSION (1) HEREBY ---- ----------- ----------- -------------- ------ Arkansas Teacher Retirement............ $ 2,505,000 1.253% 0 108,866 Baptist Health of South Florida........ 355,000 0.178% 0 15,428 Engineers Joint Pension Fund........... 235,000 0.118% 0 10,213 Nicholas Applegate Capital Management Convertible Mutual Fund ............. 435,000 0.218% 0 18,905 Polaris Vega Fund L.P.................. 3,000,000 1.500% 0 130,378 San Diego City Retirement.............. 505,000 0.253% 0 21,947 San Diego County Convertible........... 1,080,000 0.540% 0 46,936 Sunrise Partners Limited Partnership... 11,000,000 5.500% 0 478,053 Wake Forest University................. 325,000 0.163% 0 14,124 Wyoming State Treasurer................ 560,000 0.280% 0 24,337 ------------- ---------- --------- -------- Subtotal...................... $ 20,000,000 10.003% 0 869,187 ------------- ---------- --------- --------
- ---------------------------------- (1) Based upon the information provided to us by the selling securityholders, none of the current holders of the Notes beneficially owns any Class A common stock. The information presented assumes that any future transferee from any holder does not beneficially own any Class A common stock, other than Class A common stock into which the Notes are convertible at the conversion rate of 43.4594 shares per $1,000 principal amount of the Notes. Investing in the Notes and the Class A common stock issuable upon their conversion involves certain risks. See "Risk Factors" beginning on page 7 of the accompanying prospectus. Neither the securities and exchange commission nor any state securities commission has approved or disapproved of the Notes or the Class A common stock available upon conversion of the Notes or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is October 23, 2003.
-----END PRIVACY-ENHANCED MESSAGE-----